Global Inflammatory Bowel Disease Market

Inflammatory Bowel Disease Comprehensive Study by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids), Application (Hospital, Drugs Stores), Route of Administration (Oral, Injection), Cause (Genetic, Immune, Altered) Players and Region - Global Market Outlook to 2030

Inflammatory Bowel Disease Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.84%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) describes a group of disorders which are caused due to the inflammation of the intestine. Various symptoms of IBD are diarrhea, blood or mucus in stool, fever, abdominal pain, and others. In order to diagnose IBD, various tests such as C - reactive protein (CPR), Complete Blood Count (CBC), and calprotectin test are performed.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR5.84%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Inflammatory Bowel Disease market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie (United States), Janssen Biotech(United States), Sanofi (France), Takeda Pharmaceuticals (Japan), Bayer AG (Germany), Bristol-Myers Squibb (United States), Eli Lilly and Co. (United States), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (United Kingdom) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Boehringer Ingelheim GmbH (Germany), Amgen (United States), Tillotts Pharma (Switzerland) and UCB (Belgium).

Segmentation Overview
AMA Research has segmented the market of Global Inflammatory Bowel Disease market by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs) and Corticosteroids), Application (Hospital and Drugs Stores) and Region.



On the basis of geography, the market of Inflammatory Bowel Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Inflammatory Bowel Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cause, the sub-segment i.e. Genetic will boost the Inflammatory Bowel Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
R&D agreement and collaboration between the companies

Market Growth Drivers:
Rising occurrence inflammatory bowel disease and Growing number of geriatrics population

Challenges:
Patent expiry of drugs

Restraints:
Stringent government regulations towards approval of biosimilars restrain market growth

Opportunities:
The increasing involvement of key players in product development related in the field is anticipated to drive the segment

Market Leaders and their expansionary development strategies
In January 2024, Evotec has announced a collaboration with the Crohn’s & Colitis Foundation to advance drug discovery and develop new therapies for IBD, which includes Crohn’s disease and ulcerative colitis. The collaboration between Evotec and the foundation’s IBD therapeutics incubator programme aims to translate academic research into medical innovations for patients with IBD, a debilitating chronic medical condition.
In June 2023, Aster Medcity announced the opening of the Aster Inflammatory Bowel Disease Centre at the hospital. The new center is dedicated to providing specialized services for individuals suffering from Inflammatory Bowel Diseases (IBD). This multidisciplinary approach ensures comprehensive care and support for individuals with these conditions.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Inflammatory Bowel Disease Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-inflammatory Biologics
  • Non-Steroidal Anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
By Application
  • Hospital
  • Drugs Stores
By Route of Administration
  • Oral
  • Injection

By Cause
  • Genetic
  • Immune
  • Altered

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising occurrence inflammatory bowel disease
      • 3.2.2. Growing number of geriatrics population
    • 3.3. Market Challenges
      • 3.3.1. Patent expiry of drugs
    • 3.4. Market Trends
      • 3.4.1. R&D agreement and collaboration between the companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Inflammatory Bowel Disease, by Type, Application, Route of Administration, Cause and Region (value) (2018-2023)
    • 5.1. Introduction
  • 6. Inflammatory Bowel Disease: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. AbbVie (United States)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Janssen Biotech(United States)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Sanofi (France)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Takeda Pharmaceuticals (Japan)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Bayer AG (Germany)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Bristol-Myers Squibb (United States)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Eli Lilly and Co. (United States)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. F. Hoffmann-La Roche (Switzerland)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. GlaxoSmithKline plc (United Kingdom)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Pfizer Inc. (United States)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Inflammatory Bowel Disease Sale, by Type, Application, Route of Administration, Cause and Region (value) (2025-2030)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Research Programs/Design for This Report
  • Table 12. Key Data Information from Secondary Sources
  • Table 13. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 5. AbbVie (United States) Revenue: by Geography 2023
  • Figure 6. Janssen Biotech(United States) Revenue, Net Income and Gross profit
  • Figure 7. Janssen Biotech(United States) Revenue: by Geography 2023
  • Figure 8. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 9. Sanofi (France) Revenue: by Geography 2023
  • Figure 10. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 11. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 12. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 13. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 14. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 15. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 16. Eli Lilly and Co. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Eli Lilly and Co. (United States) Revenue: by Geography 2023
  • Figure 18. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2023
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2023
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Janssen Biotech(United States)
  • Sanofi (France)
  • Takeda Pharmaceuticals (Japan)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly and Co. (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Boehringer Ingelheim GmbH (Germany) , Amgen (United States) , Tillotts Pharma (Switzerland) , UCB (Belgium)
Select User Access Type

Key Highlights of Report


Mar 2024 214 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Inflammatory Bowel Disease Market Quantitative research analysis
Global Inflammatory Bowel Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie (United States), Janssen Biotech(United States), Sanofi (France), Takeda Pharmaceuticals (Japan), Bayer AG (Germany), Bristol-Myers Squibb (United States), Eli Lilly and Co. (United States), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (United Kingdom) and Pfizer Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"R&D agreement and collaboration between the companies" is seen as one of major influencing trends for Inflammatory Bowel Disease Market during projected period 2023-2030.
The Inflammatory Bowel Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Inflammatory Bowel Disease Market Report?

Have a Query? Click Here

Other Related Reports

Organ Transplant Immunosuppressant Drugs Comprehensive Study by Type (Chemical Composition, Fungal Product, Biologics), Application (Liver Transplant, Kidney Transplant, Other Organ Transplant), Drug...
$ 3650
Tissue Engineering Comprehensive Study by Type (Synthetic Materials, Biologically Derived Materials, Others), Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin...
$ 3450
Autoimmune Disease Therapeutics Comprehensive Study by Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Others), Distribution Channel (Hospitals, Clinic...
$ 3750
Impingement Syndrome Comprehensive Study by Type (Structural Impingement, Functional Impingement), Application (Hospitals, Physical Therapists), Treatment (Physical Therapy, Medications (Aspirin, Nap...
$ 3750
Blood Plasma Derivatives Comprehensive Study by Type (Albumin, Anti-Thrombin III, Intravenous Immunoglobulin (IVIG), Fresh Frozen Plasma (FFP), Others), Application (Hemophilia A, Hemophilia B, HIV, ...
$ 3750
Stem Cell Therapy Comprehensive Study by Type (Autologous, Allogeneic), Application (CNS, CVS, GIT, Wounds and Injuries, Musculoskeletal, Eye, Immune System, Others), Cell Source (Adipose tissue, Bon...
$ 3750